The EHS Task Force has been set up due to the considerable success with the launching of the annual European Health Summit. This platform has been designed to drive policy in the domain of health, aside from organising high-level annual events.
The aim is not only to create a larger healthcare network and provide visibility, but also to be able to steer the process of policy making at the European level and strengthen the link between public and private partnership through the involvement of cross-sectorial stakeholders.


Sandra Gallina

Director General DG SANTE

István Ujhelyi

Member of the European Parliament

Sirpa Pietikäinen

Member of the European Parliament

Csaba Kontor

Health Attaché, Permanent Representation of Hungary to the European Union

Antonella Cardone

CEO Cancer Patients Europe

Martine Pergent

President of International Patient Organization for Primary Immunodeficiencies (IPOPI)

Lilia Luchianov

Policy Officer, DG SANTE

Heike Prinz

Head of Commercial Operations EMEA for the Pharmaceuticals Division and ExCo Member at Bayer AG

Elizabeth Kuiper

Associate Director at European Policy Centre

Patrick Stockebrandt

Head of Division at the Centre for European Policy

Elisabetta Zanon

Director of EU Public Affairs and Advocacy of the Alliance for Regenerative Medicine (ARM)

Enrico Lugli

Group Leader and Head of Facility at Humanitas Research Hospital

Laura Campo

Executive Director International Corporate Affairs, Alzheimer’s disease, Eli Lilly and Company

Ruediger Gatermann

Senior Director EU Policy Strategy at CSL Behring

Mehul Mehta

Chief Medical Officer, Dentons Global Advisors

Mariam Zaidi

Euronews, Euractiv, CNBC Presenter

Sarah-Taïssir Bencharif

EU Health Journalist

Arnaud Thysen

Director General, European Business Summits

Felicia Balan

Partnership Manager, European Business Summits

Alvaro De Lecea

Project Assistant, European Business Summits


10 MAY 2023 

Closed meeting


The revision of the EU’s Pharma Strategy offers a once in a generation opportunity to highlight to current shortcomings and opportunities in EU health policy when it comes to rare and non-communicable diseases (cardiovascular disease, diabetes etc.). Given the nature of public-private partnerships in the healthcare landscape, listening to the voices of industry is a key factor when it comes to fostering innovation and translating this into improved patient outcomes.

8 JUNE 2023 

Residence Palace, Brussels

European Health Summit Summer Edition

12 SEPTEMBER 2023 

Closed meeting 


AI offers unprecedented opportunities for healthcare, such as reduced costs, increased automation and rapid data processing. On the other hand, questions of data privacy, bias and vulnerabilities may also increase health inequalities. As the EU moves towards the implementation of the EHDS, engaging with stakeholders and ensuring that opportunities can be properly harnessed will be essential for its success.

8 NOVEMBER 2023 

Closed meeting

How will the EU pharmaceutical legislation affect competitiveness and innovation in Europe?

As the evolution of the EU pharmaceutical legislation is still being addressed by the stakeholders involved in the sector, some concerns about its potential impact on investment, innovation, and market conditions have been raised. Within the industry, there is apprehension that the regulatory frameworks proposed may pose challenges, potentially hindering investment and innovation, which could, in turn, affect Europe’s competitiveness and attraction compared to its global counterparts. The question now is which points of the pharmaceutical legislation should be revitalised to not only attract investment and stimulate innovation but also to safeguard Europe’s competitiveness in the global market, improve access to medicines and ensure the well-being of the patients.

Have a question? Contact our team!

Felicia Balan



+32 (0) 4 89 75 55 78


Alvaro De Lecea

Project Manager


+32 (0) 2 349 3 595

Untitled design-102
Untitled design-103